Fundamental Analysis of ADC THERAPEUTICS SA(NYSE:ADCT) stock

Fundamental Rating

ADCT gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 588 industry peers in the Biotechnology industry. ADCT may be in some trouble as it scores bad on both profitability and health. ADCT is quite expensive at the moment. It does show a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year ADCT has reported negative net income.

In the past year ADCT has reported a negative cash flow from operations.

ADCT had negative earnings in each of the past 5 years.

In the past 5 years ADCT always reported negative operating cash flow.

1.2 Ratios

ADCT has a worse Return On Assets (-67.47%) than 63.01% of its industry peers.

		Industry Rank	Sector Rank
ROA	-67.47%
ROE	N/A
ROIC	N/A

ROA(3y)-44.77%

ROA(5y)-53.37%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

ADCT has a Gross Margin of 96.25%. This is amongst the best in the industry. ADCT outperforms 97.09% of its industry peers.

The Profit Margin and Operating Margin are not available for ADCT so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	96.25%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

ADCT does not have a ROIC to compare to the WACC, probably because it is not profitable.

Compared to 1 year ago, ADCT has more shares outstanding

Compared to 5 years ago, ADCT has more shares outstanding

ADCT has a worse debt/assets ratio than last year.

2.2 Solvency

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	N/A

ROIC/WACCN/A

WACC5.15%

2.3 Liquidity

A Current Ratio of 4.97 indicates that ADCT has no problem at all paying its short term obligations.

ADCT has a Current ratio (4.97) which is comparable to the rest of the industry.

A Quick Ratio of 4.73 indicates that ADCT has no problem at all paying its short term obligations.

The Quick ratio of ADCT (4.73) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
Current Ratio	4.97
Quick Ratio	4.73

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

ADCT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -45.77%.

The Revenue for ADCT has decreased by -66.87% in the past year. This is quite bad

Measured over the past years, ADCT shows a very strong growth in Revenue. The Revenue has been growing by 129.19% on average per year.

EPS 1Y (TTM)-45.77%

EPS 3YN/A

EPS 5YN/A

EPS growth Q2Q-243.33%

Revenue 1Y (TTM)-66.87%

Revenue growth 3YN/A

Revenue growth 5Y129.19%

Revenue growth Q2Q-75.95%

3.2 Future

ADCT is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 15.19% yearly.

Based on estimates for the next years, ADCT will show a very strong growth in Revenue. The Revenue will grow by 36.58% on average per year.

EPS Next Y25.4%

EPS Next 2Y17.02%

EPS Next 3Y15.19%

EPS Next 5YN/A

Revenue Next Year18.23%

Revenue Next 2Y16%

Revenue Next 3Y29.21%

Revenue Next 5Y36.58%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ADCT. In the last year negative earnings were reported.

Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ADCT. No positive earnings are expected for the next year.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as ADCT's earnings are expected to grow with 15.19% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y17.02%

EPS Next 3Y15.19%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for ADCT!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

ADC THERAPEUTICS SA

NYSE:ADCT (4/25/2024, 7:04:00 PM)

After market: 4.5 +0.06 (+1.35%)

4.44

-0.34 (-7.11%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)

Earnings (Next)

Inst Owners

Inst Owner Change

Ins Owners

Ins Owner Change

Market Cap366.43M

Analysts

Price Target

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)

Div Incr Years

Div Non Decr Years

Ex-Date

Surprises & Revisions

EPS beat(2)

Avg EPS beat(2)

Min EPS beat(2)

Max EPS beat(2)

EPS beat(4)

Avg EPS beat(4)

Min EPS beat(4)

Max EPS beat(4)

EPS beat(8)

Avg EPS beat(8)

EPS beat(12)

Avg EPS beat(12)

EPS beat(16)

Avg EPS beat(16)

Revenue beat(2)

Avg Revenue beat(2)

Min Revenue beat(2)

Max Revenue beat(2)

Revenue beat(4)

Avg Revenue beat(4)

Min Revenue beat(4)

Max Revenue beat(4)

Revenue beat(8)

Avg Revenue beat(8)

Revenue beat(12)

Avg Revenue beat(12)

Revenue beat(16)

Avg Revenue beat(16)

PT rev (1m)

PT rev (3m)

EPS NQ rev (1m)

EPS NQ rev (3m)

EPS NY rev (1m)

EPS NY rev (3m)

Revenue NQ rev (1m)

Revenue NQ rev (3m)

Revenue NY rev (1m)

Revenue NY rev (3m)

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA

EPS(TTM)

EPS(NY)

Fwd EY

FCF(TTM)

FCFY

OCF(TTM)

OCFY

SpS

BVpS

TBVpS

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-67.47%
ROE	N/A
ROCE
ROIC
ROICexc
ROICexgc
OM	N/A
PM (TTM)	N/A
GM	96.25%
FCFM

ROA(3y)

ROA(5y)

ROE(3y)

ROE(5y)

ROIC(3y)

ROIC(5y)

ROICexc(3y)

ROICexc(5y)

ROICexgc(3y)

ROICexgc(5y)

ROCE(3y)

ROCE(5y)

ROICexcg growth 3Y

ROICexcg growth 5Y

ROICexc growth 3Y

ROICexc growth 5Y

OM growth 3Y

OM growth 5Y

PM growth 3Y

PM growth 5Y

GM growth 3Y

GM growth 5Y

F-Score

Asset Turnover0.2

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio	4.97
Quick Ratio	4.73
Altman-Z

F-Score

WACC

ROIC/WACC

Cap/Depr(3y)

Cap/Depr(5y)

Cap/Sales(3y)

Cap/Sales(5y)

Profit Quality(3y)

Profit Quality(5y)

Growth

EPS 1Y (TTM)-45.77%

EPS 3YN/A

EPS 5Y

EPS growth Q2Q

EPS Next Y25.4%

EPS Next 2Y

EPS Next 3Y

EPS Next 5Y

Revenue 1Y (TTM)-66.87%

Revenue growth 3YN/A

Revenue growth 5Y

Revenue growth Q2Q

Revenue Next Year

Revenue Next 2Y

Revenue Next 3Y

Revenue Next 5Y

EBIT growth 1Y

EBIT growth 3Y

EBIT growth 5Y

EBIT Next Year

EBIT Next 3Y

EBIT Next 5Y

FCF growth 1Y

FCF growth 3Y

FCF growth 5Y

OCF growth 1Y

OCF growth 3Y

OCF growth 5Y

ADC THERAPEUTICS SA (ADCT)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens